Continuous Intravenous Administration of Granulocyte-Colony-Stimulating Factors-A Breakthrough in the Treatment of Cancer Patients with Febrile Neutropenia.
G-CSF
cancer
chemotherapy
febrile
neutropenia
Journal
Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208
Informations de publication
Date de publication:
30 Jun 2021
30 Jun 2021
Historique:
received:
06
04
2021
revised:
17
05
2021
accepted:
21
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
6
7
2021
Statut:
epublish
Résumé
(1) Background: Febrile neutropenia (FN) remains one of the most challenging problems in medical oncology and is a very severe side effect of chemotherapy. Its late consequences, when it is recurrent or of a severe grade, are dose reduction and therapy delays. Current guidelines allow the administration of granulocyte-colony-stimulating factors (G-CSF) for profound FN (except for the case when a pegylated form of G-CSF is administrated with prophylactic intention) in addition to antibiotics and supportive care. (2) Methods: This is a prospective study that included 96 patients with confirmed malignancy, treated with chemotherapy, who developed FN during their oncological therapy, and were hospitalized. They received standard treatment plus a dose of G-CSF of 16 µg/Kg/day IV continuous infusion. (3) Results: The gender distribution was almost symmetrical: Male patients made up 48.96% and 51.04% were female patients, with no significance on recovery from FN (
Identifiants
pubmed: 34208815
pii: medicina57070675
doi: 10.3390/medicina57070675
pmc: PMC8305666
pii:
doi:
Substances chimiques
Granulocyte Colony-Stimulating Factor
143011-72-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Br J Cancer. 1988 Jul;58(1):64-9
pubmed: 2458748
J Natl Cancer Inst. 2001 Jan 3;93(1):31-8
pubmed: 11136839
Br J Haematol. 1997 Aug;98(2):474-9
pubmed: 9266953
Theor Biol Med Model. 2012 Jul 30;9:32
pubmed: 22846180
J Gastrointestin Liver Dis. 2016 Jun;25(2):213-8
pubmed: 27308653
Am J Hematol. 2014 Mar;89(3):243-8
pubmed: 24178750
Cochrane Database Syst Rev. 2014 Oct 30;(10):CD003039
pubmed: 25356786
J Natl Compr Canc Netw. 2020 Jan;18(1):12-22
pubmed: 31910384
Blood. 2011 Apr 21;117(16):4349-57
pubmed: 21224471
Cancer Chemother Pharmacol. 1996;38(1):9-12
pubmed: 8603458
Int J Hematol. 1999 Feb;69(2):81-8
pubmed: 10071455
J Clin Oncol. 2015 Oct 1;33(28):3199-212
pubmed: 26169616
Clin Cancer Res. 1997 May;3(5):705-11
pubmed: 9815739
Tumori. 2014 Sep-Oct;100(5):491-8
pubmed: 25343541
Adv Biol Regul. 2017 Jan;63:132-139
pubmed: 27658318
Ann Oncol. 2016 Sep;27(suppl 5):v111-v118
pubmed: 27664247
Bone Marrow Transplant. 2002 May;29(9):727-30
pubmed: 12040468
Clin Cancer Res. 2008 Oct 15;14(20):6354-63
pubmed: 18927273
J Clin Pharmacol. 2010 Sep;50(9 Suppl):101S-112S
pubmed: 20881223
J Theor Biol. 2009 Mar 7;257(1):27-44
pubmed: 19007795
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Pediatr Blood Cancer. 2005 Sep;45(3):274-80
pubmed: 15806544
Sci Signal. 2016 Dec 20;9(459):ra124
pubmed: 27999173
Adv Ther. 2018 Nov;35(11):1816-1829
pubmed: 30298233
J Emerg Med. 2019 Nov;57(5):689-700
pubmed: 31635928